Marbodin

Memantine, the active ingredient in Marbodin, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat moderate to severe Alzheimer’s disease dementia in adults. GNH USA supplies Marbodin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine acts on the glutamatergic pathway and is indicated for dementia related to Alzheimer’s disease. - Alzheimer’s disease (moderate to severe): improves cognition and functional abilities by reducing excitotoxic neuronal damage.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Hypertension

Serious or Rare Side Effects: - Seizures - Hallucinations or psychosis - Cardiac arrhythmias - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic injury - Suicidal thoughts or behavior

Before initiating therapy, clinicians should consider several safety aspects. - Renal function: adjust dose in moderate to severe renal impairment. - Seizure history: monitor closely for new or worsening seizures. - Cardiovascular disease: assess blood pressure and heart rhythm. - Hepatic impairment: use with caution and monitor liver enzymes. - Concomitant NMDA antagonists: avoid combined use due to additive neuro‑psychiatric effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine or other NMDA antagonists: increased risk of neuro‑psychiatric side effects. - Ketamine: additive CNS effects and potential toxicity.

Moderate Interactions (Monitor Closely): - Acetylcholinesterase inhibitors (e.g., donepezil): may enhance therapeutic effect but require monitoring. - Diuretics (e.g., furosemide): can raise plasma memantine levels. - NSAIDs: may increase risk of edema or hypertension.